You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(9939.HK)直線拉昇大漲14% 普克魯胺臨牀試驗於第14天達到主要終點
格隆匯 03-11 13:10
格隆匯3月11日丨開拓藥業-B(9939.HK)午後直線拉昇,現報19.76港元,大漲14.35%,暫成交7275萬港元,最新總市值73億港元。開拓藥業今日午間發佈普克魯胺治療COVID-19重症患者的臨牀試驗結果。於臨牀試驗中,普克魯胺於第14天達到主要終點,表明世界衞生組織COVID-19等級量表下由5.663的基線下降4.01至1.653,而對照組則由5.618的基線下降0.25至5.368(p值低於0.0001)。普克魯胺同樣表明了可降低92%患者死亡風險(3.7%對比47.6%)並縮短住院時間中位數9天(住院時間中位數5天對比14天)。瑞銀近日發研報首予開拓藥業“買入”評級,目標價28.5港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account